Process for Preparing Cannabinoid-Containing Oral Pharmaceutical Composition
Summary
The European Patent Office granted Patent EP3351242A1 to Prati, Donaduzzi & Cia LTDA and Universidade De São Paulo for a process preparing a cannabinoid-containing oral pharmaceutical composition. The patent covers compositions for treating neurological and psychiatric conditions including seizures, Parkinson's disease, and anxiety disorders. The oral formulation can be delivered as a liquid, softgel, or powder.
What changed
The EPO published Patent EP3351242A1 granting exclusive rights to a process for preparing a cannabinoid-containing oral pharmaceutical composition. The patent application, filed by Prati, Donaduzzi & Cia LTDA and Universidade De São Paulo, covers therapeutic uses including treatment of seizures (A61P 25/08), movement disorders (A61P 25/16), schizophrenia (A61P 25/18), anxiety (A61P 25/20), pain (A61P 25/04), and addiction (A61P 25/22).
Manufacturers developing cannabinoid-based oral pharmaceuticals should conduct freedom-to-operate analyses given this granted European patent. The designated states cover all major European markets including DE, FR, GB, IT, ES, and NL. Pharmaceutical companies in the EU should assess whether their cannabinoid formulations may fall within the scope of this patent claims.
What to do next
- Monitor patent portfolio for freedom-to-operate considerations if developing cannabinoid-based oral pharmaceuticals
- Review IPC classifications A61P 25/08, A61P 25/16, A61P 25/18, A61P 25/20 for relevant therapeutic applications
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PROCESS FOR PREPARING A CANNABINOID-CONTAINING ORAL PHARMACEUTICAL COMPOSITION
Publication EP3351242A1 Kind: A1 Apr 08, 2026
Applicants
Prati, Donaduzzi & Cia LTDA, Universidade De São Paulo
Inventors
DONADUZZI, Luiz, DONADUZZI, Carmen Maria, DE MENEZES, Christian Gregory Burgos, JUNIOR, Liberato Brum, FILHO, Volnei José Tondo, ROSA, Patricia Moura, CRIPPA, José Alexandre, HALLAK, Jaime Eduardo Cecilio, ZUARDI, Antonio Waldo, GUIMARÃES, Francisco Silveira
IPC Classifications
A61K 31/352 20060101AFI20190405BHEP A61K 47/44 20170101ALI20190405BHEP A61K 47/10 20170101ALI20190405BHEP A61K 9/08 20060101ALI20190405BHEP A61P 25/00 20060101ALI20190405BHEP A61P 25/08 20060101ALI20190405BHEP A61P 25/16 20060101ALI20190405BHEP A61P 25/18 20060101ALI20190405BHEP A61P 25/20 20060101ALI20190405BHEP A61P 25/04 20060101ALI20190405BHEP A61P 25/22 20060101ALI20190405BHEP A61P 43/00 20060101ALI20190405BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.